Collegium Pharmaceutical Inc (NASDAQ:COLL) Beats Q3 2025 Estimates and Raises Full-Year Guidance

Collegium Pharmaceutical Inc (NASDAQ:COLL) has reported financial results for the third quarter of 2025, delivering performance that exceeded analyst expectations and prompting the company to raise its full-year financial guidance. The earnings release has been met with a significant positive reaction in pre-market trading.

Earnings and Revenue Versus Estimates

The company posted a strong quarter, with both revenue and earnings per share coming in ahead of market forecasts.

• Revenue: Collegium reported record quarterly net revenue of $209.4 million, a 31% increase compared to the same period last year. This figure substantially surpassed the analyst consensus estimate of approximately $193 million for the quarter.
• Earnings Per Share: The company reported non-GAAP adjusted earnings per share (EPS) of $2.25. This outperformed the analyst estimate of $2.08 per share.

The market's immediate reaction has been decidedly positive. Shares of Collegium are trading significantly higher in the pre-market session, indicating investor approval of the earnings beat and the subsequent guidance raise.

Updated 2025 Financial Guidance

Bolstered by the strong third-quarter results, Collegium's management has increased its financial outlook for the full year 2025. The updated guidance now exceeds the previously provided analyst estimates for the company's annual performance.

• Net Revenue Guidance: Raised to a range of $775 to $785 million, up from the prior guidance of $745 to $760 million. The new midpoint of $780 million sits above the analyst sales estimate of approximately $766 million.
• Adjusted EBITDA Guidance: Increased to a range of $460 to $470 million, up from the previous range of $440 to $455 million.

Key Business Highlights from the Quarter

The record financial performance was driven by strength across both of Collegium's core business units.

• ADHD Business: The company's neuropsychiatry business, led by Jornay PM®, saw prescriptions grow 20% year-over-year. Net revenue for Jornay PM reached $41.8 million, and the number of prescribing healthcare providers hit an all-time high of 27,700.
• Pain Portfolio: Collegium's portfolio of pain management products generated record net revenue of $167.6 million, an 11% increase year-over-year. All three core products—Belbuca®, Xtampza® ER, and the Nucynta® Franchise—reported growth compared to the prior year.
• Financial Position: The company ended the quarter with a strong cash position of $285.9 million in cash, cash equivalents, and marketable securities. It also generated $78.4 million in cash from operations during the quarter.

Conclusion

Collegium Pharmaceutical's third-quarter earnings report demonstrates robust operational and financial execution. The company not only exceeded analyst expectations for the quarter but also raised its full-year guidance to levels that outpace existing market forecasts. The strong pre-market stock performance reflects investor confidence in Collegium's growth trajectory, driven by its differentiated pain portfolio and the accelerating adoption of Jornay PM.

For a more detailed look at Collegium's earnings and future estimates, you can review the data here.

Disclaimer: This article is for informational purposes only and is not intended as investment advice. All data and figures are sourced from the company's press release and third-party estimates. Readers should conduct their own research before making any investment decisions.